2012 Announcements

See attached PDF.

Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) wishes to advise in accordance with the terms and conditions of issue that the following unquoted conditional performance rights have lapsed and forfeited. Number Exercise price CUVAK Conditional Performance Rights subject to various performance milestones 252,250 $Nil Consequently, in combination with the new issue of shares upon exercise of conditional performance rights disclosed in the following Appendix 3B, there are now 1,846,029 unquoted conditional performance rights on issue and 35,000 unlisted share options on issue. - End - For more information contact:Darren KeamyCompany SecretaryClinuvel Pharmaceuticals LimitedT: +61 3 9660 4900E: This email address is being protected from spambots. You need JavaScript enabled to view it. …

Presentation and speaking notes delivered by Clinuvel's CEO at the company's 2012 Annual General Meeting in Melbourne.

Results of resolution votes from Clinuvel's 2012 Annual General Meeting.

Rule 4.7B Quarterly report for entities admitted on the basis of commitments Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005. Name of entity CLINUVEL PHARMACEUTICALS LIMITED ABN Quarter ended (“current quarter”) 88 089 644 119 30 SEPTEMBER 2012 Consolidated statement of cash flows   Cash flows related to operating activities   Current quarter$A’000 Year to date (3 months) $A’000 1.1 Receipts from customers - - 1.2 Payments for        (a)   staff costs (b) advertising and marketing (c) research and development (d) leased assets (e) other working capital   (889) (23) (532) (58) (351)   (889) (23) (532) (58) (351) 1.3 Dividends received 1.4…

Preliminary results on four patients participating in a Phase IIa study in vitiligo (CUV102) Melbourne, Australia and Baar, Switzerland, October 16 2012 Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that preliminary observations from the company’s open label Phase IIa US pilot trial of SCENESSE® in four patients with vitiligo (CUV102) have been published in the international journal Archives of Dermatology. In total 56 patients are participating in the trial, with results from the six month treatment period expected to be released before the end of 2012. The article – “The Efficacy of Afamelanotide and Narrowband UV-B…

Melbourne, Australia and Baar, Switzerland, October 2 2012 Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced it will hold its 2012 Annual General Meeting of shareholders on Tuesday November 20, 2012 at 10.00am AEST at Grant Thornton Audit (Vic) Pty Ltd, Level 2, 215 Spring Street, Melbourne, Australia. A formal Notice of Meeting and the company’s Annual Report will be lodged with the ASX no later than October 19, 2012. – End – About Clinuvel Pharmaceuticals Limited Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the…